A new phase one clinical trial of a potential vaccine for the SARS-CoV2 coronavirus began on Monday in Seattle, with the first person to enroll in the trial receiving the vaccine.
The phase one study aims to test three different doses of the mRNA-1273 vaccine add hopes to recruit 45 healthy adults for the initial trial. Participants will receive two shots of the vaccine, 28 days apart and will be monitored to evaluate both the safety and immunogenicity of the vaccine. The latter involves seeing how well the vaccine stimulates an immune response to a protein on the SARS-CoV2 coronavirus surface.
The vaccine, mRNA-1273, was developed by biotechnology company Moderna in combination with researchers from the National Institutes of Health (NIH). The trial is being conducted at Kaiser Permanente Washington Health Research Institute in Seattle.
The first person to get the vaccine was 43-year old Jennifer Haller from Seattle who said; “I hope that we get to a working vaccine quickly and that we can save lives and people can go back to life as soon as possible,” reported in an interview.
The study is still enrolling healthy people aged 18-55 in the Seattle area to help test the new vaccine.
See What’s Next in Tech With the Fast Forward Newsletter
Tweets From @varindiamag
Nothing to see here - yet
When they Tweet, their Tweets will show up here.
